Whole body protein turnover in children with human immunodeficiency virus (HIV) infection.
The purpose of this study was to determine the rate of whole body protein turnover (WBPT) in human immunodeficiency virus (HIV)-infected children, and to determine the relationship between WBPT and growth. The rate of WBPT was calculated from the cumulative excretion of labeled urinary ammonia after a single intravenous dose of 15N-glycine in three groups of children: 1) HIV+ with growth retardation (HIV+ Gr); 2) HIV+ with normal growth (HIV+); and 3) HIV-uninfected with normal growth (HIV-). Twenty-six children between 2 and 11 y of age were studied (10 HIV+ Gr, 12 HIV+, 4 HIV-). All children were afebrile and free of acute infection during the study. Rates of WBPT (mean +/- SD) for the study groups were: HIV+ Gr, 12.2 +/- 4.8; HIV+, 10.7 +/- 5.1; and HIV-, 8.6 +/- 2.1 g.protein.kg-1.d-1 (NS, P > 0.05). Although not statistically significant, mean WBPT was 42% greater in HIV+ Gr, and 24% greater in HIV+ compared to HIV-. Statistically significant correlations were found between WBPT and Z scores for height (r = -0.39, P = 0.05) and weight-for-age (r = -0.51, P = 0.01) and dietary intake of protein (r = 0.39, P = 0.05), and between protein balance (synthesis-catabolism) and intakes of energy (r = 0.47, P = 0.02) and protein (r = 0.40, P = 0.04). There was no statistically significant correlation between WBPT and resting energy expenditure (r = 0.27, P = 0.19), or CD4 cell number (r = 0.05, P = 0.82). These data suggest an association between increased rates of protein turnover and low weight and height-for-age Z scores, and that it may be possible to achieve positive protein balance given an adequate intake of nutrients.
Henderson
R A
RA
Department of Pediatrics and Center for Human Nutrition, Johns Hopkins Schools of Medicine and Public Health, Baltimore, Maryland, USA. robinh@dhmh.state.md.us
Talusan
K
K
Hutton
N
N
Yolken
R H
RH
Caballero
B
B
D000641:Ammonia / Q000652:urine; D001481:Basal Metabolism; D001827:Body Height; D001835:Body Weight; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D005998:Glycine / Q000008:administration & dosage / Q000378:metabolism; D006130:Growth Disorders / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D015658:HIV Infections / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D018023:HIV Seronegativity / Q000502:physiology; D006801:Humans; D008297:Male; D009587:Nitrogen Isotopes; D011506:Proteins / Q000378:metabolism*
D009587:Nitrogen Isotopes; D011506:Proteins; D000641:Ammonia; D005998:Glycine